This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eric Caumes, MD
Département des maladies infectieuses et tropicales Parasitologie-Mycologie et Santé Publique Hôpital Pitié-Salpêtrière 75013 Paris Cedex, France

Annick Datry, MD; Ruben Mayorga, MD; Philippe Gaxotte, MD; Martin Danis, MD; Marc Gentilini, MD
Paris, France

Arch Dermatol. 1994;130(7):932.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Larva currens is the most typical cutaneous manifestation of human strongyloidiasis.¹ The recommended therapy for strongyloidiasis is oral tiabendazole or albendazole, but the former is poorly tolerated while the latter is poorly effective.² Oral ivermectin, the current drug of choice for onchocerciasis,³ has recently been reported as very effective and well tolerated in patients with gastrointestinal helminthiases, such as strongyloidiasis.^4,5 These findings prompted us to test this drug in three cases of larva currens.

Report of Cases. Case 1.

A 38-year-old man weighing 66 kg was first seen in August 1990. He was born in Brazil and had lived there up until 1987. He complained of recurrent episodes of watery diarrhea, abdominal discomfort, and nausea; larva currens appeared in 1985. The blood count showed mild hypereosinophilia (0.7x10⁹/L) and a stool test was positive for Strongyloides stercoralis larvae. We treated him with 2 tablets of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?